Literature DB >> 12000138

Androgen-selective gene regulation in the prostate.

B Haendler1.   

Abstract

Androgens are essential for normal prostate growth and function but are also intimately associated with prostate cancer, an important cause of mortality in the ageing male population. The effects of androgens are mediated via a specific androgen receptor (AR) belonging to the nuclear receptor family and acting as a ligand-dependent transcription factor. The AR is built in a modular fashion and composed of a long N-terminal region with transactivation functions, a central DNA-binding domain, an intermediate hinge region and a C-terminal ligand-binding domain with additional transactivation functions. In its inactive form, the AR is complexed to heat-shock proteins, and mainly cytoplasmic. Following activation, the AR enters the nucleus, binds to its cognate DNA response elements as a homodimer and stimulates gene transcription. Various cofactors directly interact with the AR to modulate gene transcription. In addition, cross-talk between the AR and other signalling pathways has been proven for several prostate-expressed genes. Understanding the intricate networks underlying androgen-selective gene regulation represents a formidable challenge but might also offer the chance to identify new drug targets for the treatment of prostate carcinoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12000138     DOI: 10.1016/s0753-3322(01)00159-7

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  4 in total

1.  OTEX, an androgen-regulated human member of the paired-like class of homeobox genes.

Authors:  Christoph Geserick; Bertram Weiss; Wolf-Dieter Schleuning; Bernard Haendler
Journal:  Biochem J       Date:  2002-08-15       Impact factor: 3.857

2.  A novel function of caspase-8 in the regulation of androgen-receptor-driven gene expression.

Authors:  Wei Qi; Hong Wu; Lin Yang; Douglas D Boyd; Zhengxin Wang
Journal:  EMBO J       Date:  2006-12-14       Impact factor: 11.598

Review 3.  Characterization of tumor differentiation factor (TDF) and its receptor (TDF-R).

Authors:  Izabela Sokolowska; Alisa G Woods; Mary Ann Gawinowicz; Urmi Roy; Costel C Darie
Journal:  Cell Mol Life Sci       Date:  2012-10-18       Impact factor: 9.261

4.  Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.

Authors:  Tatsuo Sugawara; Simon J Baumgart; Ekaterina Nevedomskaya; Kristin Reichert; Holger Steuber; Pascale Lejeune; Dominik Mumberg; Bernard Haendler
Journal:  Int J Cancer       Date:  2019-03-23       Impact factor: 7.396

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.